Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 613 who wrote (2113)	2/27/2002 4:24:10 PM
From: Cacaito	Respond to of 2515

"Doesn't tumor shrinkage generally corollate with longer life? " Not always, and the FDA demands the proof of same from every company and everydrug, nothing unusual. It is a "surrogate" marker, this is an effect that usually acompanies the most important primary outcome like survival or improve quality of life. Just in the recent past the FDA approved under the same "surrogate" conditions the following drugs: Gleevec, Netisiride (Scios) Zevalin (Idec) Amylin (approvable), bottom line the process is very fair.